Appointment dossier — Prostate Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05125016 · Phase 1 / Phase 2 — A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (United States)
- NCT06866938 · Phase 2 — Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer (France)
- NCT07476001 · Phase 2 — Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC (United States)
- NCT06244004 · Phase 2 — FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial (United States)
- NCT07354919 · Phase 2 — Axelopran for Advanced Cancer in Patients Receiving Opioids (United States)
- NCT04175431 · Phase 2 — Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study (United States)
- NCT06347705 · Phase 2 — A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer (United States)
- NCT07149831 · Phase 1 — A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults (China)
- NCT07006727 · Phase 1 — Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors (United States)
- NCT04857502 · Early Phase 1 — 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer (United States)
- NCT07077239 — Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity (United States)
- NCT07605936 — Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study (Ireland)
- NCT04472338 — Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study (United States)
- NCT07131956 — Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy (Germany)
- NCT06579911 — Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer (Austria)
- NCT06978296 — HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS) (France)
- NCT02705846 — Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations (United Kingdom)
- NCT07318051 — Sample Collection for Ongoing Research and Product Evaluation Study (United States)
Most-relevant first: trials that name Prostate Cancer, then broader trials you may still qualify for. 1204 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT05125016), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?